kaal:position:2026-07-31-3415

Epigenetics in ovarian cancer should be assessed against Kaal's source-bound claim that Facts-based, ex-post, trial-and-error rulemaking cannot anticipate the regulatory issues created by innovation, so rulemakers may not realize, or may realize far too late, what new regulatory demands a given innovation generates. The current metadata indicates a plausible connection through dynamic regulation, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

regulation of innovative products and markets
existing regulatory framework built on stable rules
External evidence level: abstract indexed.
Mapping review tier: ambiguity triage before claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

Epigenetics in ovarian cancer

Scholarly basis

kaal:claim:2957645-002
Kaal, Dynamic Regulation via Contingent Capital (2017). SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2957645
Source PDF sha256: 250b10782a5ea5dece9235a7f711aee408feaf36f2e78e310d589b5ee6304be2

Evidence and mapping

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.2297
Mapping ambiguous: true

Topics

dynamic-regulationinnovation

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0014 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: 6d8d07fb60f37b4f406f8e9d1e6e0d2fd7cb65baccecce4e8cedfd4c13430a1a
curl -s https://wulfkaal.github.io/positions/2026-07-31-3415.md | sha256sum